216 related articles for article (PubMed ID: 9632281)
1. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross NC; Apperley J; Szydlo R; Goldman JM
Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
3. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
[TBL] [Abstract][Full Text] [Related]
4. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
5. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
[TBL] [Abstract][Full Text] [Related]
6. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A
Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
8. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M
Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
[TBL] [Abstract][Full Text] [Related]
9. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
11. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
13. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
14. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
[TBL] [Abstract][Full Text] [Related]
15. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.
Raiola AM; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Bregante S; di Grazia C; Dominietto A; Soracco M; Romagnani C; Vassallo F; Casini M; Bruno B; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 2003 Apr; 31(8):687-93. PubMed ID: 12692609
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.
Yakoub-Agha I; Mesnil F; Kuentz M; Boiron JM; Ifrah N; Milpied N; Chehata S; Esperou H; Vernant JP; Michallet M; Buzyn A; Gratecos N; Cahn JY; Bourhis JH; Chir Z; Raffoux C; Socié G; Golmard JL; Jouet JP;
J Clin Oncol; 2006 Dec; 24(36):5695-702. PubMed ID: 17116940
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of recurrent chronic myelogenous leukemia in allogeneic marrow transplant recipient with the donor leukocyte transfusion, without induction of acute graft-versus-host disease].
Yamazaki H; Nakao S; Takamatsu H; Ito T; Ueda M; Shiobara S; Matsuda T
Rinsho Ketsueki; 1995 Jul; 36(7):677-81. PubMed ID: 7563596
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.
Mackinnon S; Hows JM; Goldman JM; Arthur CK; Hughes T; Apperley JF; Jones L; Batchelor JR; Brookes P; Catovsky D
Exp Hematol; 1990 Jun; 18(5):421-5. PubMed ID: 2338131
[TBL] [Abstract][Full Text] [Related]
20. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
